RUBIVet: Rapid Urine based Bacteria Identification for Veterinary Applications

RUBIVet：兽医应用中基于尿液的快速细菌鉴定

• 批准号: 84374
• 金额: $ 11.91万
• 依托单位: FLUORETIQ LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=84374
• 关键词: RUBIVet; Rapid; Urine; based; Bacteria

According to a recent survey of 532 veterinary surgeries by the Royal College of Veterinary Surgeons, 99% had noticeable reductions in weekly turnover, with 66% reporting reductions of 51% or more, as a result of social distancing measures implemented during the covid-19 pandemic. 451 of the 532 veterinary surgeries also reported that they had now moved to remote consultations which included new and repeat prescribing. 2-day laboratory testing has been the main stay for diagnosis of bacterial infections for nearly a century and is inherently sub-optimal for remote consultations. Our motivation is to challenge this distinct lack of innovation in this market and address the growing frustration amongst modern veterinarian with a simple, all-in-one solution to urine testing in animals.In this project, we will be working closely with veterinary market leaders Anvajo GmBH, to deliver a rapid bacterial identification platform on Anvajo's pre-existing fluidlab R-300 device. This would maintain the same quality of results expected from a full laboratory analysis at a fraction of time, cost and inconvenience of the gold standard.

根据皇家兽医学院（College of Veterinary Surgeons）最近对532家兽医诊所进行的调查，99%的诊所每周营业额显著减少，其中66%的诊所表示减少51%或以上，原因是在2019冠状病毒病疫情期间实施了社交距离措施。532家兽医诊所中有451家还报告说，他们现在已经转向远程咨询，包括新的和重复的处方。2-近世纪来，日间实验室测试一直是诊断细菌感染的主要手段，并且对于远程咨询来说本质上是次优的。我们的动机是挑战这个市场上明显缺乏创新，并解决现代兽医对动物尿液检测的日益增长的挫折感。在这个项目中，我们将与兽医市场领导者Anvajo GmBH密切合作，在Anvajo现有的fluidlab R-300设备上提供快速细菌鉴定平台。这将保持从一个完整的实验室分析预期的相同质量的结果，在一小部分的时间，成本和不便的黄金标准。